bioTheranostics Release: Lifetime’s “The Balancing Act” Show For Women To Discuss The Breast Cancer Index Molecular Test
Airing February 25, the program will focus on understanding unmet needs in the management of early stage, estrogen receptor-positive breast cancer after patients have completed five years of treatment, and how the BCI molecular test can help inform decision-making beyond five years
--(BUSINESS WIRE)--bioTheranostics:
WHAT:
Lifetime’s “The Balancing Act” will feature a discussion about important developments in the management of early stage, estrogen receptor-positive (ER+) breast cancer, including understanding the risk of recurrence beyond year five, side-effects of long-term hormonal drugs, and how to create a more personalized treatment plan with the Breast Cancer IndexSM (BCI). BCI is a gene expression-based test that quantifies risk of breast cancer recurrence and predicts which patients have a high likelihood of benefitting from extended adjuvant endocrine therapy. BCI testing is performed on a patient’s tumor sample and provides valuable patient-specific information.
Help employers find you! Check out all the jobs and post your resume.
--(BUSINESS WIRE)--bioTheranostics:
WHAT:
Lifetime’s “The Balancing Act” will feature a discussion about important developments in the management of early stage, estrogen receptor-positive (ER+) breast cancer, including understanding the risk of recurrence beyond year five, side-effects of long-term hormonal drugs, and how to create a more personalized treatment plan with the Breast Cancer IndexSM (BCI). BCI is a gene expression-based test that quantifies risk of breast cancer recurrence and predicts which patients have a high likelihood of benefitting from extended adjuvant endocrine therapy. BCI testing is performed on a patient’s tumor sample and provides valuable patient-specific information.
Help employers find you! Check out all the jobs and post your resume.